Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check18 days agoChange DetectedThe page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a revision update to v2.16.1. Additionally, specific studies related to Nivolumab and Ipilimumab have been removed.SummaryDifference3%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check61 days agoChange DetectedThe webpage has been updated to reflect a new version of the clinical trial study, with significant changes in the study's focus and eligibility criteria for participants. The previous version's detailed description of the study's purpose and drug combinations has been largely removed.SummaryDifference48%
- Check68 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 3, 2025.SummaryDifference0.2%
- Check75 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous version (v2.14.2) and date of March 3, 2025.SummaryDifference0.1%
Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.